Horn Aylward & Bandy
General
Cases5
Challenger50%
Patent Owner50%
NPE50%
--
--
Practice Areas
BiotechMech Eng, ManufCommunications
Top Attorneys
Elite Ratings
DCTPTABCAFC
Analytics
Lawyers
Cases
Ratings Trends
Practice Areas
Recent Dockets
Entered | Case | Description |
---|---|---|
01/29/25 | USCA for the FEDERAL CIRCUIT JUDGMENT as to (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG. (snc) (Entered: 01/29/2025) | |
01/29/25 | OPINION of USCA for the FEDERAL CIRCUIT as to (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG USCA Decision: AFFIRMED. (snc) (Entered: 01/29/2025) | |
01/29/25 | USCA JUDGMENT as to (344 in 1:24-md-03103-TSK-JPM, 258 in 1:24-cv-00039-TSK-JPM) Notice of Appeal filed by Regeneron Pharmaceuticals, Inc., (250 in 1:23-cv-00106-TSK-JPM, 259 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Samsung Bioepis Co., Ltd., (801 in 1:22-cv-00061-TSK-JPM, 190 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (258 in 1:24-md-03103-TSK-JPM, 268 in 1:23-cv-00094-TSK-JPM) Notice of Appeal filed by Samsung Bioepis, CO., LTD.,, (244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD.,, (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG, (176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis Co., Ltd., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. (snc) (Entered: 01/29/2025) | |
01/29/25 | OPINION of USCA for the FEDERAL CIRCUIT as to (344 in 1:24-md-03103-TSK-JPM, 258 in 1:24-cv-00039-TSK-JPM) Notice of Appeal filed by Regeneron Pharmaceuticals, Inc., (250 in 1:23-cv-00106-TSK-JPM, 259 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Samsung Bioepis Co., Ltd., (801 in 1:22-cv-00061-TSK-JPM, 190 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (258 in 1:24-md-03103-TSK-JPM, 268 in 1:23-cv-00094-TSK-JPM) Notice of Appeal filed by Samsung Bioepis, CO., LTD., (244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD.,, (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG, (176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis Co., Ltd., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. USCA for the FEDERAL CIRCUIT Decision: AFFIRMED. (snc) (Entered: 01/29/2025) | |
01/29/25 | USCA JUDGMENT as to (344 in 1:24-md-03103-TSK-JPM, 258 in 1:24-cv-00039-TSK-JPM) Notice of Appeal filed by Regeneron Pharmaceuticals, Inc., (250 in 1:23-cv-00106-TSK-JPM, 259 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Samsung Bioepis Co., Ltd., (801 in 1:22-cv-00061-TSK-JPM, 190 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (258 in 1:24-md-03103-TSK-JPM, 268 in 1:23-cv-00094-TSK-JPM) Notice of Appeal filed by Samsung Bioepis, CO., LTD.,, (244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD.,, (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG, (176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis Co., Ltd., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. (snc) (Entered: 01/29/2025) | |
01/29/25 | OPINION of USCA for the FEDERAL CIRCUIT as to (344 in 1:24-md-03103-TSK-JPM, 258 in 1:24-cv-00039-TSK-JPM) Notice of Appeal filed by Regeneron Pharmaceuticals, Inc., (250 in 1:23-cv-00106-TSK-JPM, 259 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Samsung Bioepis Co., Ltd., (801 in 1:22-cv-00061-TSK-JPM, 190 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (258 in 1:24-md-03103-TSK-JPM, 268 in 1:23-cv-00094-TSK-JPM) Notice of Appeal filed by Samsung Bioepis, CO., LTD., (244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD.,, (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG, (176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis Co., Ltd., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. USCA for the FEDERAL CIRCUIT Decision: AFFIRMED. (snc) (Entered: 01/29/2025) | |
10/21/24 | STIPULATION AND ORDER REGARDING CASE MANAGEMENT. Signed by Chief District Judge Thomas S. Kleeh on 10/21/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00089-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 10/21/2024) |